Positive Results for Neovasc's Reducer System Treatment for Refractory Angina Published in Cardiology Journal

- Tiara Clinical Updates presented at TVT and ISMICS Medical Conferences - 
 
VANCOUVER, June 20, 2016 - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ:NVCN - News) (TSX:NVC.TO -News) reported today that the positive results of a single center, retrospective study using the Reducer product were published in the June 14, 2016 issue of The Netherlands Heart Journal in an article titled "Safety and efficacy of a device to narrow the coronary sinus for the treatment of refractory angina: A single center real world experience". The paper documented the results from 23 consecutive patients who were implanted with the Reducer in order to treat their severe refractory angina. 
 
The published results demonstrated that in all 23 patients the Reducer device was successfully implanted in a day hospital setting without any adverse events. After a median follow-up of 9 months (range 8 – 14 months) it was found that 17 of 23 patients showed at least one class improvement in their Canadian Cardiovascular Society (CCS) angina score: 8 patients (34.8%) improved by 1 CCS class, 7 (30.4%) by 2 CCS classes and 2 (8.7%) by 3 CCS classes.
Read more: Neovasc Inc ( NVC / NVCN )

Zimmer Biomet to Acquire LDR to Enhance Innovation and Growth of Spine Business

Significantly Expands Portfolio of Innovative Solutions for $10 Billion Spine Market
Positions Company to Capitalize on Faster Growing Spine Segments, including Cervical Disc Replacement
Companies to Host Conference Call at 8:00 AM ET
 
WARSAW, Ind. and AUSTIN, Texas, June 07, 2016 -- Zimmer Biomet Holdings, Inc. (ZBH) (ZBH) (Zimmer Biomet or the Company), a global leader in musculoskeletal healthcare, and LDR Holding Corporation (LDRH) (LDR), a global medical device company focused on designing and commercializing novel and proprietary surgical technologies for the treatment of patients suffering from spine disorders, today announced that both Boards of Directors have approved a definitive agreement under which Zimmer Biomet will commence a tender offer to acquire all of the outstanding shares of LDR for $37.00 per share in cash, which implies a transaction value of approximately $1.0 billion.  The transaction is subject to customary closing conditions and is expected to close in the third quarter of 2016.
Read more: LDR Holding Corporation ( LDRH )

CombiMatrix Launches Next Generation Sequencing for Pre-Implementation Genetic Screening

High sensitivity and specificity PGS testing by Next Generation Sequencing supports healthy pregnancies and builds on prenatal diagnostics portfolio
 
IRVINE, Calif., June 01, 2016 -- CombiMatrix Corporation (CBMX), a molecular diagnostics company specializing in DNA-based testing services for pre-implantation genetic diagnostics and screening, miscarriage analysis, prenatal and pediatric diagnostics, announces that it will begin accepting samples for pre-implantation genetic screening (PGS) by next generation sequencing (NGS) in mid-June. 
 
PGS is a test performed on embryos of couples undergoing an in vitro fertilization (IVF) procedure and is designed to examine embryos for chromosomal abnormalities prior to implantation. This procedure reduces the risk for miscarriage and abnormal pregnancies and increases the success rate of the implantation and of a normal pregnancy. 
Read more: CombiMatrix Corporation ( CBMX )

NeuroMetrix Announces Availability of Quell in Approximately 1,000 Chain Drug Stores

WALTHAM, Mass.-- NeuroMetrix, Inc. (NURO) announced today that Quell® will be available, beginning in June 2016, in approximately 1,000 chain drug stores as part of a retail test with the two largest US drug retailers.
 
"Consumers have told us that they expect to see and purchase Quell at leading chain drug stores," said Shai N. Gozani, M.D., Ph.D., President and CEO of NeuroMetrix. "We are therefore delighted to broaden the availability of Quell, our proprietary, 100% drug free technology for the relief of widespread chronic pain. As Quell represents a new level of technology at premium pricing we will use learning from this test to optimize our full retail expansion.”
 
Quell is FDA cleared and designed for millions of people suffering from chronic pain. Quell gives users the option to start, stop, and adjust therapy discreetly via their smartphone. It also enables advanced sleep tracking that provides feedback on eight dimensions of sleep including sleep duration, quality, body position, time out of bed, and repetitive leg movements throughout the night. Quell is available at select healthcare professionals and retailers. To find a Quell retailer near you, visit the Store Locator at QuellRelief.com.
Read more: NeuroMetrix Inc ( NURO )

Milestone Scientific Announces Completion of Enrollment in Clinical Trials for Its Epidural Instrument

LIVINGSTON, NJ--(May 26, 2016) -Milestone Scientific Inc (NYSE MKT: MLSS) today announced it has completed enrollment in its COMPASS Study (CompuFlo® Assessment Study), a randomized, controlled, parallel group, multicenter, pivotal study to assess the safety and effectiveness of the epidural space verification with the CompuFlo® Epidural Computer Controlled System. The clinical trial for the epidural instrument reached its target of enrolling 400 patients and consists of two separate arms: (i) pain management; and (ii) labor and delivery. Both arms will be compared against the current medical standards of care. The goal of the pivotal IDE clinical trial is to demonstrate the accuracy of the CompuFlo technology in identifying and confirming the epidural space location.
Read more: Milestone Scientific Inc ( MLSS )

Videos / Webinars

View all videos

Pepperstone | Metatrader 4 Forex Broker